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1. Definition
Text Image Drop Zone
A very concise definition of the disease (maximum 300 characters, including spaces). Do not provide 
a classification of different sub-entities or a differential diagnosis here. Drag your JPEG image(s) here. Minimum size: 480 x 320 pixels
2. Clinical Presentation
2.1. Symptoms
Text Image Drop Zone
A list of all potential symptoms that may lead patients to seek medical attention (maximum 500 
characters, including spaces)
Drag your JPEG image(s) here. Minimum size: 480 x 320 pixels
2.2. Physical Findings and Signs
Text Image Drop Zone
A list of all physical findings likely to be encountered at first presentation (maximum 500 characters, 
including spaces).
Drag your JPEG image(s) here. Minimum size: 480 x 320 pixels.
Up to 10 representative images can be shown.
2.3. Chronology
Text Image Drop Zone
If applicable, provide a chronology of symptoms and physical findings at the time of presentation 
(maximum 1,000 characters, including spaces). Tables and/or graphs  will be converted into pop-up 
images.
Drag your JPEG image(s) here. Minimum size: 480 x 320 pixels. Tables and/or graphs will later be 
converted into pop-up images.
3. Diagnosis
Generalities - Description Text
3.1. Laboratory findings
Text Image Drop Zone
A list of laboratory findings that may help establish a diagnosis (maximum 1,000 characters, including 
spaces). Up to 10 representative images can be shown(format JPG, 480 x 320 pixels)
Drug-induced liver injury (DILI) refers to liver diseases that are caused by drugs, phytotherapeutics 
and other potentially toxic substances via a large range of mechanisms. As a general rule, DILI can 
mimic all forms of acute and chronic liver disease with regard to symptoms, signs and histology.
Typical symptoms of acute DILI are abdominal discomfort, fatigue, nausea and vomiting. Acute 
severe and cholestatic DILI may also present with jaundice and dark urine. Asymptomatic 
presentation is possible for mild forms and early stages. Chronic DILI may present with any 
symptoms related to liver disease.
Jaundice and dark urine are signs of hyperbilirubinemia that may be present in acute severe and 
cholestatic DILI. Immune-mediated DILI can present with fever, rash and eosinophilia as signs of 
hypersensitivity. Chronic DILI may present with any signs of hepatic disease.
Country: Switzerland
City: Zurich
Zip Code: 8091
Address: Rämistrasse 100
Institution/Office/Surgery: University Hospital Zurich, Department of Clinical Pharmacology
Diagnosis of DILI is primarily clinical and based on three principle criteria: 1. Temporal relationship with drug use; 2. Exclusion of other possible causes (1. and 2. referred to as "intrinsic evidence"); 3. 
Knowledge of a drug's hepatotoxic potential and signature pattern from previous reports ("extrinsic evidence"). Detailed and if necessary repeated history taking is the key to diagnosis of DILI. Drug 
history must include prescription and non-prescription drugs, phytotherapeutics, illicit drug use and environmental hepatotoxins.The primary challenge is to establish a precise chronological relationship of 
all recently used drugs with symptoms, signs and laboratory abnormalities associated with DILI. Specific drugs tend to have characteristic patterns regarding latency, symptoms, signs and histology. 
These "signature patterns" can make a valuable contribution to expert evaluation of suspected cases, which remains the reference for diagnosis of DILI. In addition, standardized causality assessment 
scales support an objective and quantitative evaluation of the probability that liver disease is caused by suspected drugs (create link to section 5 scales below). Nevertheless, even standardized causality 
assessment methods are subject to interrater variability and may not eliminate diagnostic uncertainty. Genetic risk factors for DILI have also been identified, but genetic testing is currently not part of 
routine diagnostics due to limited positive as well as negative predictive value (Daly AK et al, HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 
2009;41:816-9; Russmann S et al, Pharmacogenetics of drug-induced liver injury. Hepatology 2010;52:748-61). Here is an algorithm for the diagnostic approach to DILI (create link to pop-up image with 
algorithm A1). 
First name: Stefan
Title: PD Dr.
Surname: Russmann (list Prof. Kullak as senior author here as well)
ALT, alkaline phosphatase and bilirubin are the most important diagnostic markers of acute DILI. 
They are also the basis for calculation of the R-value that distinguishes hepatocellular, cholestatic 
and mixed laboratory patterns at initial presentation (create link to R-value calculator), and for the 
diagnostic threshold criteria of acute DILI (create link to table with acute DILI criteria and Hy's law 
for acute DILI). GGT and AST are also often increased in DILI, but compared to AP and ALT, 
respectively, their diagnostic value is limited by lower specificity. The calculation of the damage 
pattern has also a prognostic value, as hepatocellular DILI is associated with a higher risk of acute 
liver failure compared to cholestatic DILI. Eosinophilia >6% can be a sign of DILI associated with 
hypersensitivity. Other laboratory findings are important for the exclusion of other causes (create link 
to section 4 differential diagnosis). Lymphocyte stimulations and specific antibodies to cytochrome 
P450-adducts are specific diagnostic tests but they can lack sensitivity and are not part of routine 
diagnostics.
R-value, criteria for acute DILI and Hy’s case calculator
R-value
Note: The R value is calculated with the initial values at first diagnosis.
Required input fields:
1. ALT value
2. ALT ULN
3. AP value
4. AP ULN.
The R-value is then calculated as follows:
        ALT value / ALT ULN 
R = -----------------------------
        AP value / AP ULN
Interpretation:
R ≥5 = Hepatocellular pattern of DILI;
R >2 and <5 = Mixed pattern of DILI;
R ≤2 = Cholestatic pattern of DILI.
Reference:
Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting.
J Hepatol 1990;11:272-6.
Criteria of acute DILI
1. ALT elevation ≥5x ULN
or
2. ALP elevation ≥2x ULN without another cause
or
3. "Hy's case" criterium: ALT elevated ≥3x ULN AND total bilirubin elevation >2x ULN AND initial AP<2xULN. 
and no other cause can be found to explain th eobserved liver injury
Reference:
Aithal et al, Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 
2011;89:806-15.
Hy’s law for acute DILI
ALT elevated ≥3x ULN AND total bilirubin elevation >2x ULN AND initial AP<2xULN.
and no other cause can be found to explain the observed liver injury
References:
1) Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation. U.S. Department of Health and 
Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER), Center for Biologics 
Evaluation and Research (CBER). July 2009; 2) Lewis JH. 'Hy's law,' the 'Rezulin Rule,' and other predictors of severe 
drug-induced hepatotoxicity: putting risk-benefit into perspective. Pharmacoepidemiol Drug Saf 2006;15:221-9; 3) 
Reuben A. Hy’s Law. Hepatology 2004;39:574-8.
Author's credits 
Email: stefan.russmann@usz.ch
A concise description on how you establish a diagnosis of this disease, i.e. the minimum diagnostic criteria (maximum 1,000 characters, including spaces). Specific classifications of sub-entities can be 
provided here (e.g. phases of HBV infection, definitions of metabolic syndrome etc.). Tables will be converted into pop-up images.
3.2. Endoscopy findings
Text Image Drop Zone
A list of endoscopy findings that may help establish a diagnosis (maximum 1,000 characters, 
including spaces). Up to 10 representative images can be shown (format JPG, 480 x 320 pixels)
3.3. Radiology findings
Text Image Drop Zone
A list of radiology findings that may help establish a diagnosis (maximum 1,000 characters, including 
spaces). Up to 10 representative images can be shown (format JPG, 480 x 320 pixels)
3.4. Histology findings
Text Image Drop Zone
A list of histopathology findings that may help establish a diagnosis (maximum 1,000 characters, 
including spaces). Up to 10 representative images can be shown (format JPG, 480 x 320 pixels)
Indometacin zone 3 necrosis DILI (presenting predominantly 
with zone 3 necrosis)
oxiplatin DILI (presenting as sinusoidal obstruction syndrome 
with obliteratin of central vein, hepatocellular necrosis, 
proliferatin of bile ducts and inflammatory infiltrates)
phenprocoumon DILI  (presenting with hepatocellular 
necrosis and portal inflammatory infiltrates with eosinophils)
3.5. Other Procedures
Text Image Drop Zone
A list of other findings that may help establish a diagnosis (maximum 1,000 characters, including 
spaces). Up to 10 representative images can be shown (format JPG, 480 x 320 pixels)
4. Differential Diagnosis
Text Links - Links to Internet Websites
A list of conditions that should be taken into consideration when establishing a differential diagnosis 
check-list (maximum 500 characters, including spaces). 
Differential diagnosis may be assisted by selected, representative images (up to 10, format JPG, 
480 x 320 pixels) or shown in the form of a table that will be converted into a pop-up image
You may also provide links to Internet websites.
5. Scores
5.1. - Score N° 1: RUCAM-CIOMS scale for hepatocellular DILI 5.2. - Score N° 2: RUCAM-CIOMS scale for cholestatic or mixed DILI 5.3 - Score N° 3: Maria and Victorino (M&V) scale 5.4 - Score N° 3: DILIN severity index for DILI
5.1.1. - Introduction / Description - Text 5.2.1. - Introduction / Description - Text
5.1.2. - Equation and/or Table … - Text, table, image… 5.2.2. - Equation and/or Table … - Text, table, image…
Provide the formula or calculator or table used for this score here.
5.1.3. - Interpretation - Text 5.2.3. - Interpretation - Text
Provide the interpretation of the score here.
In the absence of a gold standard expert evaluation is still considered as the most reliable method for diagnosis of DILI. 
However, standardized scales improve objectivity and allow quantitative assessment. Scales are frequently used in the 
regulatory and industry setting, and the RUCAM-CIOMS scale has been found to provide the best overall performance 
compared to expert evaluation. The M&V scale is somewhat simpler, but it favors hypersensitivity and generally tends to 
underestimate a causal relationship.    
5.3.2. - Equation and/or Table … - Text, table, image…
Highly probable >8, probable 6 - 8, possible 3 - 5, unlikely 1 - 2, excluded <0. If more than one drug 
is suspected the scale should be applied to each drug separately.
5.4.1. - Introduction / Description - Text
Severity index for DILI based on the DILI Network prospective study. Severity grading for specific symptoms and signs of DILI according to the NCI Common Terminology 
Criteria for Adverse Events (CTCAE) can be found at: http://evs.nci.nih.gov/ftp1/CTCAE/About.html
5.4.2. - Equation and/or Table … - Text, table, image…
see A5
5.4.3. - Interpretation - Text5.3.3. - Interpretation - Text
ERCP for exclusion of obstructive hepatobiliary disease (rare indication)
Abdominal ultrasound, CT or MRI for exclusion of obstructive hepatobiliary disease.
More than 1000 drugs have been associated with DILI. Information on a drug's hepatotoxic potential 
and its signature pattern of DILI ("extrinsic evidence") should first be searched in the prescribing 
information. Searches in the literature, specific DILI databases and standard references (e.g. 
Kaplowitz N, DeLeve LD [eds]. Drug-induced liver disease. New York, informa healthcare, 
2007) are further valuable information sources. Consider also that DILI can present with a large 
range of clinical phenotypes including immunoallergic hepatitis, autoimmune hepatitis-like, acute 
hepatic necrosis, acute viral hepatitis-like, acute liver failure, cholestatic hepatitis, bland cholestasis, 
acute fatty liver with lactic acidosis, nonalcoholic fatty liver, sinusoidal obstruction syndrome (formerly 
called venoocclusive disease), chronic hepatitis, nodular regeneration, vanishing bile duct syndrome, 
and cirrhosis.
Highly probable >8, probable 6 - 8, possible 3 - 5, unlikely 1 - 2, excluded <0. If more than one drug is 
suspected the scale should be applied to each drug separately.
see A4
5.3.1. - Introduction / Description - Text
Histology is usually not specific for DILI, and liver biopsy is therefore not part of routine diagnostic 
workup for DILI. However, liver biopsy can be indicated and make an important contribution to patient 
management when there is a complex clinical situation with several possible drug and non-drug 
causes. Histology is also useful for grading severity and can identify or establish typical histological 
signature patterns of DILI caused by specific drugs and sometimes be the first suggestion of DILI. 
The pathologist should use a systematic approach for the evaluation of possible DILI: 1. Identify the 
pathological pattern of injury and its relative severity. 2. Exclude non-DILI etiologies by clinical history 
and ancillary testing. 3. Compare known patterns of injury of the candidate agents to the biopsy 
findings, taking into account the temporal sequence of events. 4. Assess the likelihood of DILI as an 
etiology for the biopsy findings. (Ref.: Kleiner DE. The pathology of drug-induced liver injury. Semin 
Liver Dis 2009;29:364-72).
In the absence of a gold standard expert evaluation is still considered as the most reliable method for 
diagnosis of DILI. However, standardized scales improve objectivity and allow quantitative 
assessment. Scales are frequently used in the regulatory and industry setting, and the RUCAM-
CIOMS scale has been found to provide the best overall performance compared to expert evaluation. 
The M&V scale is somewhat simpler, but it favors hypersensitivity and generally tends to 
underestimate a causal relationship.    
In the absence of a gold standard expert evaluation is still considered as the most reliable method 
for diagnosis of DILI. However, standardized scales improve objectivity and allow quantitative 
assessment. Scales are frequently used in the regulatory and industry setting, and the RUCAM-
CIOMS scale has been found to provide the best overall performance compared to expert 
evaluation. The M&V scale is somewhat simpler, but it favors hypersensitivity and generally tends to 
underestimate a causal relationship.    
Viral hepatitis due to HAV, HBV, HCV, HEV, EBV, CMV, HSV. Benign obstructive hepatobiliary 
disease. Autoimmune hepatitis. Wilson's disease. Hemochromatosis. Alcoholic liver disease. 
Bacterial or fungal sepsis. Congestive heart failure, ischemic liver. Primary or metastatic 
malignancy of the liver or biliary tract. Primary biliary cirrhosis. Primary sclerosing 
cholangitis. Non-alcoholic fatty liver disease and non alcoholic steatohepatitis. Alpha 1-
antitrypsin deficiency.
see A2 see A3
For each score provide an Introduction/Description, Equation and/or Table, an Interpretation and a Reference. Provide scores commonly used and internationally accepted for diagnosis. Each score 
will open a new screen level (screen level four).
3 examples of histology pictures (also provided separately as jpg files): DILI induced by indometacin 
(presenting predominantly with zone 3 necrosis), oxiplatin (presenting as sinusoidal obstruction 
syndrome with obliteratin of central vein, hepatocellular necrosis, proliferatin of bile ducts and 
inflammatory infiltrates), and phenprocoumon (presenting with hepatocellular necrosis and portal 
inflammatory infiltrates with eosinophils). Histology pictures were kindly provided by Prof. Achim 
Weber, Zurich (which should be acknowledged)
Definite >17;  Probable 14–17;  Possible  10–13;  Unlikely  6–9;  Excluded  <6. If more than one drug is suspected the scale 
should be applied to each drug separately.
1=Mild; 2=Moderate; 3=Severe; 4=Fatal or transplantation
	  
RUCAM-­‐CIOMS	  scale	  for	  hepatocellular	  DILI	  
	  
1.	  Temporal	  rela=onship	  of	  start	  of	  drug	  to	  ALT>2x	  ULN	  	   	   	  Score	  
Ini%al	  treatment	  5–90	  days;	  subsequent	  treatment	  course:	  1–15	  days	   	  2	  
Ini%al	  treatment	  <5	  or	  >90	  days;	  subsequent	  treatment	  course:	  >15	  days	   	  1	  
From	  cessa%on	  of	  drug:	  <15	  days,	  or	  <15	  days	  aBer	  subsequent	  treatment 	  1	  
Otherwise	   	   	   	   	   	  0	  
	  
2.	  AFer	  drug	  cessa=on-­‐	  diﬀerence	  between	  peak	  ALT	  and	  upper	  limits	  normal	  
Decreases	  >50%	  within	  8	  days	   	   	   	   	  3	  
Decreases	  >50%	  within	  30	  days	  	   	   	   	  2	  
No	  informa%on	  or	  decrease	  >50%	  aBer	  >30	  days,	  or	  inconclusive 	  0	  
Decrease	  <50%	  aBer	  30	  days	  or	  recurrent	  increase 	   	  -­‐2	  
	  
3.	  Risk	  factors	  
No	  alcohol	  use	  (above	  recommended	  limit) 	   	   	  0	  
Alcohol	  use	  (above	  recommended	  limit) 	   	   	  1	  
Age	  <55	  years	  	   	   	   	   	   	  0	  
Age	  >55	  years	   	   	   	   	   	  1	  
	  
4.	  Concomitant	  drug 	   	   	   	  	  
No	  concomitant	  drug	  administered 	   	   	  0	  
Concomitant	  drug	  with	  sugges%ve	  or	  compa%ble	  %me	  of	  onset	   	   	  -­‐1	  
Concomitant	  known	  hepatotoxin	  with	  sugges%ve	  or	  compa%ble	  %me	  of	  onset	  	   	  -­‐2	  
Concomitant	  drug	  with	  posi%ve	  rechallenge	  or	  validated	  diagnos%c	  test	  	  	   	  -­‐3	  
	  
5.	  Nondrug	  causes:	  Six	  are	  primary:	  recent	  hepa==s	  A,	  B,	  or	  C,	  biliary	  obstruc=on,	  acute	  
alcoholic	  hepa==s	  (AST	  >	  2x	  ALT),	  recent	  hypotension	  
Secondary	  group:	  Underlying	  other	  disease;	  possible	  CMV,	  EBV	  or	  HSV	  infec=on	  	  
All	  primary	  and	  secondary	  causes	  reasonably	  ruled	  out:	   	   	  2	  
All	  6	  primary	  causes	  ruled	  out	   	   	   	   	  1	  
4	  or	  5	  primary	  causes	  ruled	  out	  	   	   	   	  0	  
<	  4	  primary	  causes	  ruled	  out	  (max.	  nega%ve	  score	  for	  items	  4	  and	  5:	  –4) 	  -­‐2	  
Nondrug	  cause	  highly	  probable	  	   	   	   	  -­‐3	  
	  
6.	  Previous	  informa=on	  on	  hepatotoxicity	  of	  the	  drug	  in	  ques=on	  
Package	  insert	  or	  labeling	  men%on	   	   	   	  2	  
Published	  case	  reports	  but	  not	  in	  label	   	   	   	  1	  
Reac%on	  unknown	   	   	   	   	  0	  
	  
7.	  Rechallenge	  
Posi%ve	  (ALT	  doubles	  with	  drug	  in	  ques%on	  alone)	   	   	  3	  
Compa%ble	  (ALT	  doubles	  with	  same	  drugs	  as	  given	  before	  ini%al	  reac%on) 	  1	  
Nega%ve	  (Increase	  in	  ALT	  but	  <2x	  ULN,	  same	  condi%ons	  as	  when	  	  
reac%on	  occurred)	   	   	   	   	  -­‐2	  
Not	  done,	  or	  indeterminate	  result	   	   	   	  0	  
	  
Total:	  
	  
	  
RUCAM-­‐CIOMS	  scale	  for	  cholesta=c	  or	  mixed	  DILI	  
	  
1.	  Temporal	  rela=onship	  of	  start	  of	  drug	  to	  ALP>2x	  ULN	  	   	  	  	   	  Score	  
Ini%al	  treatment	  5–90	  days;	  subsequent	  treatment	  course:	  1–90	  days	   	  2	  
Ini%al	  treatment	  <5	  or	  >90	  days;	  subsequent	  treatment	  course:	  >90	  days	   	  1	  
From	  cessa%on	  of	  drug:	  <30	  days,	  or	  <30	  days	  aBer	  subsequent	  treatment 	  1	  
Otherwise	   	   	   	   	   	  0	  
	  
2.	  AFer	  drug	  cessa=on	  -­‐	  diﬀerence	  between	  peak	  ALP	  or	  total	  bilirubin	  and	  ULN 	  	  
Decreases	  >50%	  within	  180	  days	   	   	   	  2	  
Decreases	  <50%	  within	  180	  days	   	   	   	  1	  
Persistence	  or	  increase	  or	  no	  informa%on	  	   	   	   	  0	  
If	  drug	  is	  con%nued	  –	  inconclusive	   	   	   	  0	  
	  
3.	  Risk	  factors 	  	  
No	  alcohol	  use	  (above	  recommended	  limit) 	   	   	  0	  
Alcohol	  use	  (above	  recommended	  limit) 	   	   	  1	  
Age	  <55	  years	  	   	   	   	   	   	  0	  
Age	  >55	  years	   	   	   	   	   	  1	  
	  
4.	  Concomitant	  drug 	  	  
No	  concomitant	  drug	  administered 	   	   	  0	  
Concomitant	  drug	  with	  sugges%ve	  or	  compa%ble	  %me	  of	  onset	   	   	  -­‐1	  
Concomitant	  known	  hepatotoxin	  with	  sugges%ve	  or	  compa%ble	  %me	  of	  onset	  	   	  -­‐2	  
Concomitant	  drug	  with	  posi%ve	  rechallenge	  or	  validated	  diagnos%c	  test	  	  	   	  -­‐3	  
	  
5.	  Nondrug	  causes:	  Six	  are	  primary:	  recent	  hepa==s	  A,	  B,	  or	  C,	  biliary	  obstruc=on,	  acute	  alcoholic	  
hepa==s	  (AST	  >	  2x	  ALT),	  recent	  hypotension	  
Secondary	  group:	  Underlying	  other	  disease;	  possible	  CMV,	  EBV	  or	  HSV	  infec=on	   	  	  
All	  primary	  and	  secondary	  causes	  reasonably	  ruled	  out:	   	   	  2	  
All	  6	  primary	  causes	  ruled	  out	   	   	   	   	  1	  
4	  or	  5	  primary	  causes	  ruled	  out	  	   	   	   	  0	  
<	  4	  primary	  causes	  ruled	  out	  (max.	  nega%ve	  score	  for	  items	  4	  and	  5:	  –4) 	  -­‐2	  
Nondrug	  cause	  highly	  probable	  	   	   	   	  -­‐3	  
	  
6.	  Previous	  informa=on	  on	  hepatotoxicity	  of	  the	  drug	  in	  ques=on 	  	  
Package	  insert	  or	  labeling	  men%on	   	   	   	  2	  
Published	  case	  reports	  but	  not	  in	  label	   	   	   	  1	  
Reac%on	  unknown	   	   	   	   	  0	  
	  
7.	  Rechallenge 	  	  
Posi%ve	  (ALT	  doubles	  with	  drug	  in	  ques%on	  alone)	   	   	  3	  
Compa%ble	  (ALT	  doubles	  with	  same	  drugs	  as	  given	  before	  ini%al	  reac%on) 	  1	  
Nega%ve	  (Increase	  in	  ALT	  but	  <2x	  ULN,	  same	  condi%ons	  as	  when	  	  
reac%on	  occurred)	   	   	   	   	  -­‐2	  
Not	  done,	  or	  indeterminate	  result	   	   	   	  0	  
	  
Total: 	  	  
Maria	  and	  Victorino	  scale	  for	  DILI	  
	  
1.	  Temporal	  rela=onship	  between	  drug	  intake	  and	  the	  onset	  of	  clinical	  picture	  	   	  Score	  
A.	  Time	  from	  drug	  intake	  un%l	  the	  onset	  of	  clinical	  or	  laboratory	  manifesta%ons	  
	  	  	  	  	  4	  days	  to	  8	  weeks	  (or	  less	  than	  4	  days	  in	  cases	  of	  reexposure)	   	   	  3	  
	  	  	  	  	  Less	  than	  4	  days	  or	  more	  than	  4	  weeks 	   	   	   	  1	  
	  
B.	  Time	  from	  the	  withdrawal	  of	  the	  drug	  un%l	  the	  onset	  of	  manifesta%ons	  
	  	  	  	  	  0	  to	  7	  days 	   	   	   	   	   	  3	  
	  	  	  	  	  8	  to	  15	  days 	   	   	   	   	   	  0	  
	  	  	  	  	  More	  than	  15	  days* 	   	   	   	   	  -­‐3	  
	  
C.	  Time	  from	  withdrawal	  of	  the	  drug	  un%l	  normaliza%on	  of	  laboratory	  values†	  
	  	  	  	  	  Less	  than	  6	  months	  (cholesta%c	  or	  mixed	  pabern)	  or	  2	  months	  (hepatocellular) 	  3	  
	  	  	  	  	  More	  than	  6	  months	  (cholesta%c	  or	  mixed)	  or	  2	  months	  (hepatocellular) 	   	  0	  
	  
2.	  Exclusion	  of	  alternate	  causes‡ 	  	  
Viral	  hepa%%s	  (HAV,	  HBV,	  HCV,	  CMV,	  EBV)	  
Alcoholic	  liver	  disease	  
Biliary	  tree	  obstruc%on	  
Preexis%ng	  liver	  disease	  
Other	  (pregnancy,	  acute	  hypotension) 	  	  
Complete	  exclusion 	   	   	   	   	  3	  
Par%al	  exclusion 	   	   	   	   	  0	  
Possible	  alterna%ve	  cause	  detected 	   	   	   	  -­‐1	  
Probable	  alterna%ve	  cause	  detected 	   	   	   	  -­‐3	  
	  
3.	  Extrahepa=c	  manifesta=ons 	  	  
Rash,	  fever,	  arthralgia,	  eosinophilia	  (>6%),	  cytopenia 	  	  
4	  or	  more 	  3	  
2	  or	  3 	  2	  
1 	  1	  
None 	  0	  
	  
4.	  Inten=onal	  or	  accidental	  re-­‐exposure	  to	  the	  drug 	  	  
Posi%ve	  rechallenge	  test 	   	  3	  
Nega%ve	  or	  absent	  rechallenge	  test 	  0	  
	  
5.	  Previous	  report	  in	  the	  literature	  of	  cases	  of	  DILI	  associated	  with	  the	  drug 	  	  
Yes	   	   	   	  2	  
No	  (drugs	  marketed	  for	  up	  to	  5	  years)	   	  0	  
No	  (drugs	  marketed	  for	  more	  than	  5	  years)	   	  -­‐3	  
	  	  
Total:	   	  	  
	  
*	  Except	  cases	  of	  prolonged	  persistence	  of	  the	  drug	  in	  the	  body	  aBer	  drug	  withdrawal	  (e.g.,	  amiodarone)	  
†	  Normaliza%on	  –	  decrease	  to	  values	  below	  2×	  the	  upper	  limit	  of	  normal	  values.	  
‡	  Use	  the	  exclusion	  criteria	  considered	  appropriate	  in	  each	  case.	  
	  
DILI	  Network	  (DILIN)	  severity	  index	  for	  DILI	  
	  
	  
Categories:	  
1	  	  -­‐	  	  Elevated	  ALT/ALP	  concentra%on	  reaching	  criteria	  for	  DILI,	  but	  bilirubin	  concentra%on	  <	  2	  ULN	  ;	  
	  
2	  	  -­‐	  Elevated	  ALT/ALP	  concentra%on	  reaching	  criteria	  for	  DILI,	  and	  bilirubin	  concentra%on	  ≥	  2	  ULN	  or	  symptoma%c	  
hepa%%s;	  
	  
3	  	  -­‐	  Elevated	  ALT/ALP	  concentra%on	  reaching	  criteria	  for	  DILI,	  bilirubin	  concentra%on	  ≥	  2	  ULN,	  and	  one	  of	  the	  following:	  
	  	  	  -­‐	  Hepa%c	  failure:	  
	  	  	  -­‐	  INR	  ≥	  1.5	  
	  	  	  -­‐	  Ascites	  and/or	  encephalopathy,	  disease	  	  	  	  	  dura%on	  <	  26	  weeks,	  absence	  of	  underlying	  cirrhosis	  	  
	  	  	  -­‐	  Other	  organ	  failure	  believed	  to	  be	  due	  to	  DILI	  (e.g.	  renal,	  pulmonary);	  
	  
4	  	  -­‐	  Death	  or	  tranplanta%on	  due	  to	  DILI.	  
	  
5.1.4. - Reference - Text 5.2.4. - Reference - Text
Provide the references of the score here.
6. Clinical course - Complications
Clinical course - Text Image Drop Zone
A schematic description of the evolution of the disease over time. This section can be divided into 
paragraphs with headings (up to 10, each should contain up to 500 characters, including spaces). Add representative images (up to 10, format JPG, 480 x 320 pixels).
7. Management and Therapy
7.1. General measures - Text
7.2. Specific measures - Text
7.2.1. Indications - Text
7.2.2. Precautions, limitations and complications - Text
7.3. Drugs
Drug 1: N-acetylcysteine (NAC) for acetaminophen-poisoning
is the only approved specific treatment of DILI.
7.3.1. Drug N° 1 7.3.2. Drug N° 2 7.3.3. Drug N° 3
Name of the drug - Text Name of the drug - Text Name of the drug - Text
7.3.1.1. Indications - Text 7.3.2.1. Indications - Text
A concise description of indications accepted for the use of each specific drug (maximum 500 
characters, including spaces). Tables will be converted into pop-up images.
A concise description of indications accepted for the use of each specific drug (maximum 500 
characters, including spaces). Tables will be converted into pop-up images.
7.3.1.2. Posology - Text 7.3.2.2. Posology - Text
A concise description of posologies accepted for the use of each specific drug (maximum 500 
characters, including spaces). Tables  will be converted into pop-up images (e.g. in case of 
adaptation according to body weight, renal insufficiency, age etc.). Also state what specific 
precautions should apply (i.e. on an empty stomach, after meals, at bedtime, after fat-rich meals, with 
water, slow perfusion etc.)
A concise description of posologies accepted for the use of each specific drug (maximum 500 
characters, including spaces). Tables  will be converted into pop-up images (e.g. in case of 
adaptation according to body weight, renal insufficiency, age etc.). Also state what specific 
precautions should apply (i.e. on an empty stomach, after meals, at bedtime, after fat-rich meals, 
with water, slow perfusion etc.)
There are protocols for intravenous and for oral administration with comparable efficacy. Intravenous 
application is preferable in patients with vomiting, non-compliance, pancreatitis, bowel complications 
or acute liver failure. Here is the 20 hour IV protocol according to Prescott et al.:
• Administer an initial loading dose of 150 mg/kg IV over 15 to 60 minutes (60 min is 
recommended)
• Next, administer a 4-hour IV infusion at 50 mg/kg per hour
• Finally, administer a 16-hour IV infusion at 100 mg/kg per hour
The required dose of NAC should be diluted in 5% dextrose as follows:
• Adults and Children>12 years: Initially 200ml over 15 mins, then 500ml over 4 hours, then 1L 
over 16 hours 
• Children<12 years, body weight >20kg: Initially 100ml over 15 mins, then 250ml over 4 hours, 
then 500ml over 16 hours 
• Children body weight <20kg: Initially 3ml/kg over 15 mins, then 7ml/kg over 4 hours, then 14 
ml/kg over 16 hours 
The treatment period may be extended if patients have large ingestions, or elevated serum 
transaminase activity or increased INR.
Reference:
Prescott et al, Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. 
Lancet 1977;2:432-4.
7.3.4. Drug N° 4
Name of the drug - Text
7.3.4.2. Posology - Text
A concise description of posologies accepted for the use of each specific drug (maximum 500 characters, including spaces). Tables  will be converted into pop-up images 
(e.g. in case of adaptation according to body weight, renal insufficiency, age etc.). Also state what specific precautions should apply (i.e. on an empty stomach, after meals, 
at bedtime, after fat-rich meals, with water, slow perfusion etc.)
5.3.4. - Reference - Text
The most important measure is the immediate discontinuation of suspicious drugs, particularly in hepatocellular DILI and Hy's law cases (create link to section 3.1 laboratory findings). On the other hand 
isolated stable elevations of transaminases without clinical symptoms of liver disease and ALT up to 3 or even 5x ULN may be tolerated and can even be reversible under continued drug therapy. 
Although, maintenance of the suspicious drug in this setting is only currently justifiable with antituberculosis therapy. Strict monitoring of ALT is required in such patients.
7.3.4.1. Indications - Text
Provide a list of precautions.
Provide a list of drugs (generic names only, no trade names are allowed) officially admitted for disease management. Avoid traditional or parallel medicine remedies that have not been licensed by official 
authorities. Each drug comprised in the list will open a new description on screen level four (see below).
1) Danan G, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method 
based on the conclusions of international consensus meetings: application to drug-induced liver 
injuries. J Clin Epidemiol 1993;46:1323-30. 2) Lucena et al, Comparison of two clinical scales for 
causality assessment in hepatotoxicity. Hepatology 2001;33:123-30. 3) Kaplowitz N. Causality 
assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001;33:308-10. 4) 
García-Cortés et al. Causality assessment methods in drug induced liver injury: Strengths and 
weaknesses. J Hepatol 2011;55:683-691.
1) Danan G, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method 
based on the conclusions of international consensus meetings: application to drug-induced liver 
injuries. J Clin Epidemiol 1993;46:1323-30. 2) Lucena et al, Comparison of two clinical scales for 
causality assessment in hepatotoxicity. Hepatology 2001;33:123-30. 3) Kaplowitz N. Causality 
assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001;33:308-10. 4) García-
Cortés et al, Causality assessment methods in drug induced liver injury: Strengths and weaknesses. 
J Hepatol 2011;55:683-691.
A concise description of indications accepted for the use of each specific measure (maximum 500 characters, including spaces). If needed, you can provide one or more tables that will be converted 
into pop-up images. Provide a concise description of the measure here (maximum 1,000 characters, including spaces).
1) Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. 
Hepatology 1997;26:664-9. 2) Lucena et al, Comparison of two clinical scales for causality assessment in hepatotoxicity. 
Hepatology 2001;33:123-30. 3) Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. 
Hepatology 2001;33:308-10. 4) García-Cortés et al, Causality assessment methods in drug induced liver injury: Strengths and 
weaknesses. J Hepatol 2011;55:683-691.
N-acetylcysteine (NAC) for acetaminophen poisoning is the only approved specific treatment for DILI. Patients that present within 4 hours after ingestion of an acetaminophen dose ≥7.5 g should also be 
treated with activated charcoal for decontamination. In addition, NAC has also proved useful in patients with idiosyncratic drug-induced acute liver failure at early stages (Lee et al, Intravenous N-
acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009;137:856-64). Assuming a generally protective effect of NAC-mediated 
antioxidant effects, glutathione replenishment and its good safety profile NAC has therefore also been considered for the treatment of less severe forms of idiosyncratic DILI. Budesonide is sometimes 
given for presumably immune-mediated DILI. However, those two approaches are not evidence-based.
A list of all specific measures that cannot be included in the list of drugs (e.g. TIPS, paracentesis, surgical procedures, chemioembolization etc.). Each measure comprised in the list will open a new 
description on screen level four (see below).
A concise description of general measures accepted for the management of the disease (e.g. lifestyle changes, type of surveillance) (maximum 1,000 characters, including spaces). 
7.3.3.2. Posology - Text
A concise description of posologies accepted for the use of each specific drug (maximum 500 characters, including spaces). 
Tables  will be converted into pop-up images (e.g. in case of adaptation according to body weight, renal insufficiency, age etc.). 
Also state what specific precautions should apply (i.e. on an empty stomach, after meals, at bedtime, after fat-rich meals, with 
water, slow perfusion etc.)
Given the extraordinary regenerative capacity of the liver most cases of acute DILI recover without 
sequelae. However, the risk of acute liver failure increases if the causative drug is not immediately 
discontinued. Hy's law cases of acute DILI (ALT elevated ≥3x ULN AND total bilirubin elevation >2x 
ULN AND initial AP<2xULN) have an ~10% risk of resulting in fatal acute liver failure or liver 
transplantation. Accordingly, these cases are of high concern and should prompt immediate 
discontinuation of suspicious drugs with detailed workups and monitoring. Cases with a 
hepatocellular enzyme pattern have a higher risk of progression to liver failure than those with a 
cholestatic pattern. Recovery from cholestatic DILI is usually prolonged over several months, but 
recovery is eventually complete in most patients, whereas permanent vanishing bile duct syndrome is 
a rare complication. Chronic DILI and sinusoidal obstruction syndrome may lead to cirrhosis.
A concise description of indications accepted for the use of each specific drug (maximum 500 characters, including spaces). 
Tables will be converted into pop-up images.
N-acetylcysteine (NAC)
Indicated for the treatment of paracetamol (acetaminophen) overdose. NAC is most effective if 
started within 8 hours after ingestion. The Prescott nomogram (attached, create link) should 
be used to guide treatment with NAC only in an unstaggered (acute ingestion) overdose, and 
only if the results for paracetamol levels are available within 8 hours of ingestion. The dose 
required for toxicity may be lower in patients with risk factors such as alcohol abuse or low 
body weight (diminished cytochrome P450 activity/reduced glutathione levels), or when 
paracetamol is co-ingested with other drugs, such as codeine which increases gut transit time 
and enzyme-inducing drugs such as phenytoin and carbemazepine. In such cases, the patient 
should be considered 'high-risk'. In all other cases of unstaggered (acute ingestion) overdose 
NAC should be started immediately. In a staggered overdose (multiple overdoses taken over a 
A concise description of indications accepted for the use of each specific drug (maximum 500 characters, including spaces). Tables will be converted into pop-up images.
7.3.3.1. Indications - Text
5.4.4. - Reference - Text
1) Aithal et al, Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011;89:806-15. 2) Fontana et al, Drug-Induced Liver Injury 
Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009;32:55-68.
7.3.1.3. Interactions - Text 7.3.2.3. Interactions - Text
A list of drugs (generic names only, no trade names are allowed) known for interacting with the drug 
under description. Add suggested measures in a very concise text (100 characters per each 
interaction, including text).
A list of drugs (generic names only, no trade names are allowed) known for interacting with the drug 
under description. Add suggested measures in a very concise text (100 characters per each 
interaction, including text).
7.3.1.4. Side Effects - Text 7.3.2.4. Side Effects - Text
A list of side effects known to be associated with the use of the drug under description. Add 
suggested measures in a very concise text (100 characters per each side effect).
A list of side effects known to be associated with the use of the drug under description. Add 
suggested measures in a very concise text (100 characters per each side effect).
7.3.1.5. Precautions - Text 7.3.2.5. Precautions - Text
Provide a list of precautions. Provide a list of precautions.
7.4. Algorithms - Text
Algorithms - Tables
8. Links of interest
Links of interest - Text List of links to Internet websites
300 characters max. 
http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/ucm071471.htm
https://dilin.dcri.duke.edu/
http://www.spanishdili.uma.es/
A list of drugs (generic names only, no trade names are allowed) known for interacting with the drug under description. Add suggested measures in a very concise text (100 
characters per each interaction, including text).
7.3.4.4. Side Effects - Text
7.3.4.5. Precautions - Text
7.3.4.3. Interactions - Text
Provide a list of precautions.
1. AASLD-FDA-NIH-PhRMA - Hepatotoxicity Special Interest Group; 2. Drug-Induced Liver Injury 
Network (DILIN); 3. Spanish DILI Registry
Physicochemical interactions with the thiol group of NAC are possible. As a precaution do not mix 
with other substances than dextrose or glucose in the infusion. NAC may enhance the vasodilatory 
effects of nitrates
The decision to stop treatment with NAC should be individualized for each patient based on the 
course of ALT and INR elevation, and measurements of acetaminophen plasma levels according to 
the Prescott nomogram (create link to nomogram as in section 7.3.1.1). 
The taste and odour of oral NAC may not be tolerated, and nausea and vomiting may be problematic. 
In Europe NAC is therefore usuallly administered iv. Three to 6% of patients given iv NAC may 
develop an anaphylactoid reaction, which can be managed by reducing the infusion rate/suspending 
the infusion until the reaction has settled. Antihistamine and beta2 agonist therapy may be effective.
Attached is an algorithm for a clinical diagnostic approach to acute DILI. In addition, referral to specialist centre in a timely fashion is paramount in order to achieve good outcomes. The 
two tables below contain what have have been suggested as referral criteria. We would, however, encourage early referral, with longitudinal assessment by telephone, where appropriate. 
Referral should not delay start of NAC administration in cases of acetaminophen poisoning if indicated.
Describe officially accepted algorithms for disease management.  As an introduction, you can provide a text of up to 500 characters, including spaces. Algorithms can be provided in the form of tables, 
that will be converted into pop-up images.
A list of side effects known to be associated with the use of the drug under description. Add suggested measures in a very 
concise text (100 characters per each side effect).
A list of drugs (generic names only, no trade names are allowed) known for interacting with the drug under description. Add 
suggested measures in a very concise text (100 characters per each interaction, including text).
A list of side effects known to be associated with the use of the drug under description. Add suggested measures in a very concise text (100 characters per each side effect).
7.3.3.3. Interactions - Text
Provide a list of precautions.
7.3.3.5. Precautions - Text
7.3.3.4. Side Effects - Text
